% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gajjar:126556,
      author       = {A. Gajjar and D. C. Bowers and M. A. Karajannis and S.
                      Leary and H. Witt$^*$ and N. G. Gottardo},
      title        = {{P}ediatric {B}rain {T}umors: {I}nnovative {G}enomic
                      {I}nformation {I}s {T}ransforming the {D}iagnostic and
                      {C}linical {L}andscape.},
      journal      = {Journal of clinical oncology},
      volume       = {33},
      number       = {27},
      issn         = {1527-7755},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2017-02584},
      pages        = {2986 - 2998},
      year         = {2015},
      abstract     = {Pediatric neuro-oncology has undergone an exciting and
                      dramatic transformation during the past 5 years. This
                      article summarizes data from collaborative group and
                      institutional trials that have advanced the science of
                      pediatric brain tumors and survival of patients with these
                      tumors. Advanced genomic analysis of the entire spectrum of
                      pediatric brain tumors has heralded an era in which
                      stakeholders in the pediatric neuro-oncology community are
                      being challenged to reconsider their current research and
                      diagnostic and treatment strategies. The incorporation of
                      this new information into the next-generation treatment
                      protocols will unleash new challenges. This review
                      succinctly summarizes the key advances in our understanding
                      of the common pediatric brain tumors (ie, medulloblastoma,
                      low- and high-grade gliomas, diffuse intrinsic pontine
                      glioma, and ependymoma) and some selected rare tumors (ie,
                      atypical teratoid/rhabdoid tumor and CNS primitive
                      neuroectodermal tumor). The potential impact of this new
                      information on future clinical protocols also is discussed.
                      Cutting-edge genomics technologies and the information
                      gained from such studies are facilitating the identification
                      of molecularly defined subgroups within patients with
                      particular pediatric brain tumors. The number of evaluable
                      patients in each subgroup is small, particularly in the
                      subgroups of rare diseases. Therefore, international
                      collaboration will be crucial to draw meaningful conclusions
                      about novel approaches to treating pediatric brain tumors.},
      cin          = {B062},
      ddc          = {050},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26304884},
      pmc          = {pmc:PMC4567701},
      doi          = {10.1200/JCO.2014.59.9217},
      url          = {https://inrepo02.dkfz.de/record/126556},
}